Latest news

Dyax Corp. and Debiopharm S.A. report positive Results from Phase IIa Clinical Trial with DX-890 (EPI-hNE4) in Children with Cystic…

ELOXATIN™ submitted in the United States and in Europe for the adjuvant treatment of patients with colon cancer

Eloxatin™ (oxaliplatin for injection) approved in the United States for the 1st line treatment of metastatic colorectal cancer

ELOXATIN® is becoming a cornerstone therapy for the treatment of metastatic colorectal cancer in Europe

Debiopharm S.A. and Dyax Corp. granted orphan drug designation for DX-890 (EPI-HNE4) by U.S. FDA – Cystic Fibrosis designation

Debiopharm S.A. seeks New Partner to Commercialise Trelstar® (Triptorelin Pamoate) in the US, Canada and Mexico for the Treatment of…

Debiopharm presents results of a first monthly injectable sustained-release fomulation of ZT-1 for Alzheimer´s Disease

Debiopharm and Tulane Cancer Center select Hemenway as the 2003 Mauvernay Research Excellence Scholar

Debiopharm SA starts a Phase II trial for a once daily oral formulation of ZT-1 to treat Alzheimer´s